Relapsed glioblastomas respond to regorafenib
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-018-0161-5
Abstract: Data from a phase II trial involving patients with relapsed glioblastoma following chemoradiotherapy, a setting in which few evidence-based therapies are currently available, demonstrate the superiority of the anti-angiogenic tyrosine-kinase inhibitor regorafenib over lomustine chemotherapy.… read more here.
Keywords: glioblastomas respond; relapsed glioblastomas; oncology; regorafenib ... See more keywords